Literature DB >> 24081887

Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany.

Daniela Eidt-Koch1, Thomas O F Wagner, Thomas Mittendorf, Andreas Reimann, J-Matthias von der Schulenburg.   

Abstract

OBJECTIVE: Objective of this study is to assess and evaluate resource use in outpatient treatment in Germany and to compare it with remuneration.
METHODS: Outpatient treatment was evaluated in seven different centers for pediatric and adult CF patients. Data were recorded during one representative month in 2006. A micro-costing approach was used to value resource use data.
RESULTS: For outpatient treatment mean costs (excluding drugs) of 488 € per patient per quarter occurred. Correlation analyses identified significant cost drivers including age and co-morbidities (pancreatic insufficiency, hepatobiliary complications, lung function capacity, or bacterial lung colonization). Remuneration covered only 51% of the total costs (252 € per patient/quarter).
CONCLUSIONS: As the human resources available to these centers today are already below the requirements set by the European consensus for standards of CF care it will be important for a high level of patient care to reach a cost-covering remuneration scheme.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Keywords:  Germany; cost analysis; cystic fibrosis; reimbursement

Mesh:

Year:  2010        PMID: 24081887     DOI: 10.1002/ppul.21364

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  3 in total

1.  Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.

Authors:  Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.981

Review 2.  Cystic Fibrosis.

Authors:  Susanne Naehrig; Cho-Ming Chao; Lutz Naehrlich
Journal:  Dtsch Arztebl Int       Date:  2017-08-21       Impact factor: 5.594

3.  Staff costs of hospital-based outpatient care of patients with cystic fibrosis.

Authors:  Helge Hollmeyer; Jonas Schreyögg; Ulrich Wahn; Doris Staab
Journal:  Health Econ Rev       Date:  2011-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.